Abstracts tagged "infection and tuberculosis"

Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting
Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India
Sarit Sekhar Pattanaik¹, Hafis Muhammed ², Amita Aggarwal ³, Able Lawrence ⁴, Vikas Agarwal ², Durga P Misra ², Latika Gupta ⁴ and Ramnath Misra ⁴, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²SGPGI, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…
Abstract Number: 10 • 2016 ACR/ARHP Annual Meeting
The Utility of Screening for Infectious Diseases in Recipients of Anti-TNF-α Therapy
Kristal Choi¹, Lester Mertz², Russell Heigh³, James Yiannias⁴ and Janis Blair⁵, ¹Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ²Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ, ³Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ, ⁴Dermatology, Mayo Clinic Arizona, Scottsdale, AZ, ⁵Infectious Diseases, Mayo Clinic Arizona, Scottsdale, AZ
The Utility of Screening for Infectious Diseases in Recipients of Anti-TNF-α Therapy Choi, Kristal, Mertz, Lester, Heigh, Russell, Yiannias, James, Blair, Janis Background/Purpose: Tumor…
Abstract Number: 2507 • 2015 ACR/ARHP Annual Meeting
A Quality Indicator for the Screening of Latent Tuberculosis Infection and the Result of Follow-up Interferon-Gamma-Release Assays in Patients with Rheumatic Disease Receiving Biologic Agents in a Japanese Hospital
Yasuhiro Suyama^1,2, Mitsumasa Kishimoto², Chisun Min³, Yuko Kataoka², Masei Suda², Ryo Rokutanda², Yukio Matsui², Ken-ichi Yamaguchi², Tokutaro Tsuda², Shunya Kaneshita², Hisanori Shimizu² and Masato Okada², ¹Rheumatology, JR Tokyo General Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Infection is one of the most devastating side effects of biologic agents use, particularly early on in the course of therapy. Prevention is considered…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].